JMP Securities Reiterates “Market Outperform” Rating for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA)‘s stock had its “market outperform” rating reiterated by analysts at JMP Securities in a research note issued to investors on Thursday,Benzinga reports. They currently have a $9.00 price objective on the stock. JMP Securities’ price objective would suggest a potential upside of 182.13% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. HC Wainwright decreased their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Trading Up 5.6 %

SVRA stock traded up $0.17 during mid-day trading on Thursday, reaching $3.19. 138,171 shares of the stock traded hands, compared to its average volume of 1,266,494. The stock’s fifty day moving average is $3.49 and its 200-day moving average is $4.00. The company has a market cap of $547.46 million, a P/E ratio of -7.42 and a beta of 0.92. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a 52-week low of $2.82 and a 52-week high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). As a group, sell-side analysts expect that Savara will post -0.45 earnings per share for the current year.

Insider Activity at Savara

In other Savara news, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This represents a 10.48 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SVRA. Choreo LLC acquired a new position in Savara during the second quarter valued at approximately $59,000. DRW Securities LLC bought a new stake in shares of Savara during the 2nd quarter worth $62,000. Virtu Financial LLC acquired a new position in Savara in the 3rd quarter valued at $67,000. Principal Financial Group Inc. raised its holdings in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after acquiring an additional 6,973 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Savara by 258.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.